
Bharat Biotech’s COVID-19 vaccine candidate has shown an interim efficacy of 81% in a Phase III trial, the company announced …

India’s vaccine developer Bharat Biotech has advised a number of groups to avoid taking its homegrown COVID-19 vaccine, Covaxin. According …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

